A dual-labelling strategy for integrated ICPMS and LIF for the determination of Peptides

Zhubao Zhang,¹ Xiaowen Yan,¹ Ming Xu,¹ Limin Yang,¹ and Qiuquan Wang* ¹, b

¹Department of Chemistry & the Key Laboratory of Analytical Sciences, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005, China; E-mail: qqwang@xmu.edu.cn; Fax: +86 592 2187400; Tel: +86 592 2181796.
²State Key Laboratory of Marine Environmental Science, Xiamen University, Xiamen 361005, China.

Chemicals
All chemicals and reagents used in this study were at least of analytical grade. Ultrapure water used throughout this study was prepared with Milli-Q system (Millipore Filter Co., Bedford, MA). Fluorescein isothiocyanate (FITC), Tris-(2-carboxyethyl)-phosphine (TCEP, ≥ 98%), vasopressin (Vas, ≥ 97%), somatostatin (Som, ≥ 98%), 4-Morpholineethanesulfonic acid (MES) and 4-Morpholonepropanesulfonic acid (MOPS) were all obtained from sigma-Aldrich (St. Louris, MO). GGYYGGC was obtained from Sangon Biotech (Shanghai) Co., Ltd. 1,4,7,10-Tetraazacyclododecane-1,4,7-trisacetic acid-10-maleimidoethylacetamide (MMA-DOTA) was purchased from Macrocyclics (Dallas, TX). ¹⁵³Eu-enriched Eu₂O₃ (99.8%) was purchased from Cambridge Isotope Laboratories, Inc. (Andover, MA). Concentrated HNO₃ (GR grade) and HPLC grade acetonitrile (ACN) were purchased from Merck KGaA (Darmstadt, Germany).

Natural isotopic abundance Eu solution for peptide labelling was prepared by dissolving the solid Eu₂O₃ (from Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, purity greater than 99.9999%) in concentrated HNO₃ at room temperature, and then evaporated gradually to dryness on an electric plate; the residue finally dissolved to a concentration of 500 mmol L⁻¹ Eu solution using 2% HNO₃. The enriched isotopic stoke solution of ¹⁵³Eu used for species-unspecific isotope dilution analysis was prepared from solid ¹⁵³Eu₂O₃ in the same way. And the final exact concentration of ¹⁵³Eu was determined via inverse isotope dilution analysis to be 2.80 μg L⁻¹.

HPLC-ESI-MS: Chromatographic separations were performed on an Agilent 1100 series chromatographic system (Agilent Technologies, Palo Alto, CA) using a Zorbax 300SB-C18 column (1.0 I.D. × 150 mm in length, 3.5μm particle size). The derivatives were eluted with the following gradient program at the flow rate of 0.05 mL min⁻¹. The mobile phase A (0.05% TFA in ultrapure water) was maintained for 5 min for desalting and then mobile phase B (0.05% TFA in ACN) was linearly increased from 25% to 60% within 30 min. The column effluent was directly introduced into a Bruker Daltonics Esquire-LC ESI ion trap mass spectrometer (Bremen, Germany)
for structural analysis of the dual-labelled peptides. The operational parameters of the ESI-MS were as follows: ion mode, positive; m/z range measured 300-2000; capillary voltage, -3300 V; nebulizer gas, 70 psi; dry gas, 8 L min⁻¹; end plate offset, -500 V; dry temperature, 300 °C.

**HPLC-ICPMS.** An LC-20AD LC system (Shimadzu, Kyoto, Japan) equipped with the same C18 column was used in HPLC-ICPMS. The gradient elution program was also the same as HPLC-ESI-MS experiments. The effluent from the column was mixed with the enriched ¹⁵³Eu spike solution continuously pumped by a syringe pump (Cole-Parmer, East Bunker Court Vernon Hills, IL) through a three-way connector for on-line quantification using an ELAN DRC II CPMS (PerkinElmer, SCIEX, Canada) equipped with a concentric pneumatic nebulizer and a Cyclonic spray chamber. The operational parameters of ICPMS were as follows: RF power, 1200W; auxiliary gas, 1.0 L min⁻¹; nebulizer gas, 0.88 L min⁻¹; plasma gas, 15 L min⁻¹; dwell time, 100 ms; isotope monitored, ¹⁵¹Eu and ¹⁵³Eu.

**CE-LIF.** The capillary electrophoretic analysis was carried out on a Beckman P/ACE capillary electrophoresis system equipped with a laser-induced fluorescence detector (the excitation wavelength were 488 nm) (Beckman Instruments, Palo Alto, CA, USA). A 40 cm length (30 cm from inlet end to the detection window) uncoated fused-silica capillary with 75 μm inner diameter was used. Unless indicated, the running buffer was Na₂CO₃-NaHCO₃ (200 mmol L⁻¹, pH 9.5). Samples were injected under pressure (0.5 psi) for 5s. The separation voltage was 5 kV at normal polarity. Prior to the runs, the capillary was rinsed with 0.1 mol L⁻¹ NaOH solution, ultrapure water and the running buffer for 2 min each in sequence, respectively.

**Subsequent labelling of -SH and -NH₂.** We chose Vas as a model peptide to optimize the proposed dual-labelling conditions. Vas was dissolved in ultrapure water to get a stock solution containing 0.92 mmol L⁻¹ Vas. The disulfide bond in Vas (10μL, 0.92 mmol L⁻¹) were reduced firstly with a fivefold molar excess (compared to the disulfide bond) of TCEP at 37 °C for 30 min in 40 μL 100 mmol L⁻¹ MOPS buffer solution (pH6.8); then MMA-DOTA was added to label the nascent –SHs at 47 °C for 40 min. Under the best labelling conditions of pH, reaction temperature and time, the molar ratios (1:1, 3:1, 5:1, 7:1, 10:1) of MMA-DOTA to –SHs were investigated.

The next Eu-loading step was performed at pH 5.8 or lower because possible precipitation of Eu³⁺ would generate at high pH. Therefore, the Vas-MMA-DOTA solution was buffered by adding appropriate amount of 500 mmol L⁻¹ MES buffer (pH 5.8). Subsequently, a 2-fold molar excess of Eu with respect to DOTA was added and reacted for 1 h at 37 °C. The excess free Eu³⁺ was depleted with EDTA and it was eluted within the dead volume during HPLC separation, making no interference with the determination of labelled peptides.

The following procedure was to label the -NH₂ in Vas with FITC. Typically, a pH of 9.0 is selected for the derivatization of -NH₂ with FITC.² Before conjugating, the pH of Vas-MMA-DOTA-Eu solution was adjusted to 9.0 with 200 mmol L⁻¹ Na₂CO₃-NaHCO₃ so as to guarantee a basic condition. Finally, different amounts of FITC (3, 5, 10, 15, 25, 35, 50-fold in excess compared to -NH₂) were added to conjugate the -NH₂ at 50°C for 12 h. Besides, time-dependent labelling of -NH₂ (in Vas-MMA-DOTA-Eu) with FITC was also investigated. In the cases of Som and GGYGGC, the labeling conditions were the same as those of Vas.
Fig. S1 Effect of the molar ratio of MMA-DOTA to -SH (in Vas) on the labelling efficiency of MMA-DOTA towards Vas. Reaction condition: 100 mmol L⁻¹ MOPS (pH 6.8) at 47 °C for 40 min, 50 μmol L⁻¹ Vas; HPLC-UV measurement (λ = 214 nm).

Fig. S2 ESI-MS spectra of a) Vas, b) MMA-DOTA labelled Vas, c) MMA-DOTA-Eu labelled Vas, d) MMA-DOTA-Eu and FITC labelled Vas, e) MMA-DOTA-Eu and FITC labelled GGYGGC, f) MMA-DOTA-Eu and FITC labelled Som. DM and TM in the MS spectra denote deconvolution and theoretical molecular weights, respectively.
Fig. S3 Effect of the molar ratio of FITC to -NH₂ (in Vas-MMA-DOTA-Eu) on labelling efficiency of FITC-Vas-MMA-DOTA-Eu. Reaction conditions: 200 mmol L⁻¹ Na₂CO₃-NaHCO₃ (pH 9.0) at 50°C, 50 μmol L⁻¹ Vas. HPLC-UV measurement (λ = 254 nm).

Fig. S4 Time-dependent labelling of -NH₂ (in Vas-MMA-DOTA-Eu) with FITC. Reaction conditions: the molar ratio of FITC to -NH₂ was 25:1, 200 mmol L⁻¹ Na₂CO₃-NaHCO₃ (pH 9.0) at 50°C, 50 μmol L⁻¹ Vas. HPLC-UV measurement (λ = 254 nm).

Quantification using HPLC coupled with species-unspecific isotope dilution ICPMS. An enriched ¹⁵³Eu spike solution was mixed continuously with the HPLC effluent so as to change the isotope ratio of ¹⁵³Eu/¹⁵¹Eu. In order to keep the flow stable and match the ICPMS requirement as well as minimize the influence of ACN in the mobile phase, the spike solution was injected at a flow rate of 1 mL min⁻¹ using an accurate syringe pump. The signal of ¹⁵³Eu and ¹⁵¹Eu were monitored, realizing the absolute quantification of the peptides.

Optimization of CE-LIF conditions for separation and determination of the peptides. For the separation and quantification of three dual-labelled model peptides, Na₂CO₃-NaHCO₃ buffer was used as a running buffer. The effect of running buffer pH from 9.2 to 10.6 on the separation efficiency was studied. Moreover, different concentrations (50, 100, 150, 200 mmol L⁻¹) of Na₂CO₃-NaHCO₃ buffer solution at optimum pH for the separation were also studied, besides the
best separation voltage was investigated. On the basis of a series of experiments, the optimal CE conditions were obtained as follows: 200 mmol L⁻¹ Na₂CO₃-NaHCO₃ (pH 9.5) used as the running buffer; the sample injected under 0.5 psi for 5s and CE separation voltage at 5 kV (normal polarity). A mixture containing completely dual-labelled Vas, GGYGGC and Som was analyzed by CE-LIF under the optimized conditions (Fig. S5 and S6). The results are shown in Fig. S7.

**Fig. S5** pH effect of running buffer on the CE separation. CE conditions: uncoated fused-silica capillary, 40 cm × 75 μm ID; running buffer: 50 mmol L⁻¹ Na₂CO₃-NaHCO₃; separation voltage: 5 kV; injection: 0.5 psi, 5s. Peak1, dual-labelled Vas; peak2, dual-labelled Som; peak3, dual-labelled GGYGGC; peak4, unreacted FITC.

**Fig. S6** Effect of running buffer concentration on the CE separation. Running buffer: Na₂CO₃-NaHCO₃ (pH 9.5). Other conditions were the same as those indicated in Fig. S5.
**Fig. S7** Electrophoregram of the dual-labelled peptides. CE conditions: uncoated fused-silica capillary, 40 cm × 75 μm ID; running buffer: 200 mM Na₂CO₃-NaHCO₃ (pH 9.5); separation voltage: 5 kV; injection: 0.5 psi, 5s. Peak1, the dual-labelled Vas; peak2, the dual-labelled Som; peak3, the dual-labelled GGYGGC; peak4, unreacted FITC.

**References**